{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T21:53:40Z","timestamp":1791496420824,"version":"4.3.4"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ageing Research Reviews"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.arr.2024.102348","type":"journal-article","created":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T15:37:46Z","timestamp":1717256266000},"page":"102348","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["Donanemab, another anti-Alzheimer's drug with risk and uncertain benefit"],"prefix":"10.1016","volume":"99","author":[{"given":"Poul F.","family":"H\u00f8ilund-Carlsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abass","family":"Alavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge R.","family":"Barrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolph J.","family":"Castellani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Herrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasper P.","family":"Kepp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael L.","family":"Neve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona-Elisabeth","family":"Revheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos K.","family":"Robakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano L.","family":"Sensi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryce","family":"Vissel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.arr.2024.102348_bib1","doi-asserted-by":"crossref","first-page":"e2114","DOI":"10.1212\/WNL.0000000000207156","article-title":"Accelerated brain volume loss caused by anti-\u03b2-amyloid drugs: a systematic review and meta-analysis","volume":"100","author":"Alves","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.arr.2024.102348_bib2","first-page":"354","article-title":"Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials","volume":"5","author":"Andrews","year":"2019","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.arr.2024.102348_bib3","unstructured":"Biogen. 2024. Biogen to Realign Resources for Alzheimer's Disease Franchise [Online]. 31 January 2024. \u3008https:\/\/investors.biogen.com\/news-releases\/news-release-details\/biogen-realign-resources-alzheimers-disease-franchise\u3009. [Accessed 04.01.2024]."},{"key":"10.1016\/j.arr.2024.102348_bib4","first-page":"197","article-title":"Two randomized phase 3 studies of aducanumab in early Alzheimer's disease","volume":"9","author":"Budd Haeberlein","year":"2022","journal-title":"J. Prev. Alzheimers Dis."},{"key":"10.1016\/j.arr.2024.102348_bib5","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3233\/JAD-221305","article-title":"Neuropathology of anti-amyloid-\u03b2 immunotherapy: a case report. 2023","volume":"93","author":"Castellani","year":"2023","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2024.102348_bib6","doi-asserted-by":"crossref","first-page":"4084","DOI":"10.1038\/s41380-023-02215-8","article-title":"The use of neuroimaging techniques in the early and differential diagnosis of dementia","volume":"28","author":"Chouliaras","year":"2023","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.arr.2024.102348_bib7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.arr.2024.102348_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2023.102112","article-title":"The proteinopenia hypothesis: loss of A\u03b242 and the onset of Alzheimer's disease","volume":"92","author":"Espay","year":"2023","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.arr.2024.102348_bib9","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1212\/01.WNL.0000159743.08996.99","article-title":"Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease","volume":"64","author":"Fox","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.arr.2024.102348_bib10","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/00031305.2018.1562983","article-title":"Informed bayesian t-test","volume":"74","author":"Gronau","year":"2020","journal-title":"Am. Stat."},{"key":"10.1016\/j.arr.2024.102348_bib11","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1212\/01.WNL.0000159740.16984.3C","article-title":"AN1792(QS-21)-201 Study Team","volume":"64","author":"Gilman","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.arr.2024.102348_bib12","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.bcp.2013.11.009","article-title":"Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: a long-range point of view beyond 2020","volume":"88","author":"Hampel","year":"2014","journal-title":"Biochem Pharm."},{"key":"10.1016\/j.arr.2024.102348_bib13","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.3390\/ijms25073892","article-title":"Alzheimer's amyloid hypothesis and antibody therapy: melting glaciers?","volume":"25","author":"H\u00f8ilund-Carlsen","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.arr.2024.102348_bib14","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.3233\/JAD-215275","article-title":"Aducanumab (Marketed as Aduhelm) approval is likely based on misinterpretation of PET imaging data","volume":"84","author":"H\u00f8ilund-Carlsen","year":"2021","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2024.102348_bib15","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.3233\/JAD-220841","article-title":"Amyloid PET: A Questionable Single Primary Surrogate Efficacy Measure on Alzheimer Immunotherapy","volume":"90","author":"H\u00f8ilund-Carlsen","year":"2022","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2024.102348_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2023.101996","article-title":"Passive Alzheimer's immunotherapy: a promising or uncertain option?","volume":"90","author":"H\u00f8ilund-Carlsen","year":"2023","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.arr.2024.102348_bib17","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3233\/JAD-130485","article-title":"Amyloid-\u03b2 positron emission tomography imaging probes: a critical review","volume":"36","author":"Kepe","year":"2013","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2024.102348_bib18","doi-asserted-by":"crossref","first-page":"3969","DOI":"10.1093\/brain\/awad159","article-title":"The amyloid cascade hypothesis: an updated critical review","volume":"146","author":"Kepp","year":"2023","journal-title":"Brain"},{"key":"10.1016\/j.arr.2024.102348_bib19","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3233\/JAD-230099","article-title":"The anti-amyloid monoclonal antibody lecanemab: 16 cautionary notes","volume":"94","author":"Kepp","year":"2023","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2024.102348_bib20","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.3233\/JAD-190220","article-title":"18F-FDG Is a superior indicator of cognitive performance compared to 18F-florbetapir in Alzheimer's disease and mild cognitive impairment evaluation: a global quantitative analysis","volume":"70","author":"Khosravi","year":"2019","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2024.102348_bib21","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3233\/JAD-200868","article-title":"The role of amyloid-\u03b2 in white matter damage: possible common pathogenetic mechanisms in neurodegenerative and demyelinating diseases","volume":"78","author":"Pietroboni","year":"2020","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2024.102348_bib22","article-title":"Scientists tie third clinical trial death to experimental Alzheimer\u2019s drug [Online]. Updated 21 December 2022","author":"Piller","year":"2022","journal-title":"Sci.\u00a0Tie\u00a0Third Clin. Trial\u00a0Death\u00a0Exp. Alzheimer\u2019S. Drug\u00a0Sci.\u00a0Aaas."},{"key":"10.1016\/j.arr.2024.102348_bib23","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/B978-0-323-85555-6.00019-9","article-title":"Lessons from antiamyloid-\u03b2 immunotherapies in Alzheimer's disease","volume":"193","author":"Plascencia-Villa","year":"2023","journal-title":"Handb. Clin. Neurol."},{"key":"10.1016\/j.arr.2024.102348_bib24","article-title":"In Alzheimer's disease, amyloid beta accumulation is a protective mechanism that ultimately fails","volume":"2022 Jun 8","author":"Rischel","year":"2022","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.arr.2024.102348_bib25","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u03b2 plaques in Alzheimer's disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.arr.2024.102348_bib26","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.arr.2024.102348_bib27","doi-asserted-by":"crossref","first-page":"8220","DOI":"10.1038\/s41467-023-43933-5","article-title":"Fatal iatrogenic cerebral \u03b2-amyloid-related arteritis in a woman treated with lecanemab for Alzheimer's disease","volume":"14","author":"Solopova","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.arr.2024.102348_bib28","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.3233\/JAD-190559","article-title":"Probing estrogen sulfotransferase-mediated inflammation with [11C]-PiB in the living human brain","volume":"73","author":"Surmak","year":"2020","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2024.102348_bib29","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-A\u03b2 protofibril antibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.arr.2024.102348_bib30","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-053012","article-title":"Comparative safety and efficacy of cognitive enhancers for Alzheimer's dementia: a systematic review with individual patient data network meta-analysis","volume":"12","author":"Veroniki","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.arr.2024.102348_bib31","article-title":"Integrated Alzheimer's disease rating scale: clinically meaningful change estimates","volume":"8","author":"Wessels","year":"2022","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.arr.2024.102348_bib32","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1001\/jama.2023.11701","article-title":"Ushering in a new era of Alzheimer disease therapy","volume":"330","author":"Widera","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.arr.2024.102348_bib33","doi-asserted-by":"crossref","first-page":"e2220","DOI":"10.1212\/WNL.0000000000011832","article-title":"Long-term effects of cholinesterase inhibitors on cognitive decline and Mortality","volume":"96","author":"Xu","year":"2021","journal-title":"Neurology"}],"container-title":["Ageing Research Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568163724001661?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568163724001661?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,21]],"date-time":"2024-07-21T15:12:40Z","timestamp":1721574760000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568163724001661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":33,"alternative-id":["S1568163724001661"],"URL":"https:\/\/doi.org\/10.1016\/j.arr.2024.102348","relation":{},"ISSN":["1568-1637"],"issn-type":[{"value":"1568-1637","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Donanemab, another anti-Alzheimer's drug with risk and uncertain benefit","name":"articletitle","label":"Article Title"},{"value":"Ageing Research Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arr.2024.102348","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102348"}}